We are leveraging our
knowledge of autophagy
biology to create
new therapeutics

Our Pipeline

Samsara is leveraging its knowledge of new autophagy biology to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious rare genetic diseases and neurodegenerative disorders with a strong genetic component. These diseases all have limited or no known treatment options.

We focus on identifying novel targets and mechanisms which have a strong genetic linkage to dysfunctional autophagy, and pair this new biology with the appropriate genetically driven disease where autophagy plays a driving role, and where we have generated strong in-house evidence of disease modification.

The Lysoseeker™ Platform

A unique approach for discovering new autophagy therapeutics.

Neurodegeneration

What if we could tackle the cause of Alzheimer’s and Parkinson’s Disease?

Rare Monogenic Disease

What if we could offer real hope for serious rare genetic diseases?

Our Pipeline

Samsara is leveraging its knowledge of new autophagy biology.

© 2021 Samsara Therapeutics | Legal Information | Privacy

© 2021 Samsara Therapeutics
Legal Information | Privacy